Leerink Swann Starts Biogen (BIIB) at Outperform; Key to Fulfilling BG-12's Blockbuster Potential
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $214.35 -3.25%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Leerink Swann initiates coverage on Biogen (NASDAQ: BIIB) with an Outperform. PT range $154-$162.
Analyst, Irene Lau, said, "BIIB is preparing to launch BG-12, and MEDACorp KOL neurologists' feedback leads us to believe the Street's apparent enthusiasm for BG-12 is well founded. We predict robust utilization across MS patient subsets. Key to fulfilling BG-12's blockbuster potential is continued long-term safety. For Amyotrophic lateral sclerosis (ALS), KOL feedback for upcoming Dexpramipexole (DEX) Phase III data (est at ALS-MND Dec-12) was encouraging, but for conservatism we do not include any revenue in our model. Assuming a conservative $23K/year DEX treatment cost, we calculate ~$5/share of NPV upside to our current DCF (pricing at $42K/year could provide ~$10/share)."
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $142.21 yesterday.
Analyst, Irene Lau, said, "BIIB is preparing to launch BG-12, and MEDACorp KOL neurologists' feedback leads us to believe the Street's apparent enthusiasm for BG-12 is well founded. We predict robust utilization across MS patient subsets. Key to fulfilling BG-12's blockbuster potential is continued long-term safety. For Amyotrophic lateral sclerosis (ALS), KOL feedback for upcoming Dexpramipexole (DEX) Phase III data (est at ALS-MND Dec-12) was encouraging, but for conservatism we do not include any revenue in our model. Assuming a conservative $23K/year DEX treatment cost, we calculate ~$5/share of NPV upside to our current DCF (pricing at $42K/year could provide ~$10/share)."
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $142.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- BMO Capital Starts D-Wave Quantum Inc. (QBTS) at Outperform
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
